Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685706 | 0.73 | — | — | |
| SCHEMBL31260402 | 0.72 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBTLR7 | |
| SCHEMBL6807516 | 0.69 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBTLR7 | |
| SCHEMBL16486305 | 0.69 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBTLR7 | |
| SCHEMBL2849211 | 0.66 | PDE4A (0.38) | PI4KAPI4K2BPI4K2API4KBCACNA1H | |
| SCHEMBL2179785 | 0.66 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6753958 | 0.65 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5924160 | 0.64 | CACNA1H (0.36) | CACNA1HTLR8 | |
| SCHEMBL10765842 | 0.63 | POLB (0.45) | — | |
| SCHEMBL21314870 | 0.61 | PNP (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720422-B2 | MODULATORS OF IMMUNE RESPONSE BY INDUCTION OF CYTOKINE BIOSYNTHESIS; SUBSTITUTED 4-PHENOXY-IMIDAZO(4,5-C)PYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | PI4KA 358/4885PI4K2B 828/4885PI4K2A 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.